Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.69 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.65 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.65 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.65 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.58 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.58 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL379282 | 1.00 | SLC7A5 (0.69) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Leucine SCHEMBL2057302 | 0.88 | SLC7A5 (0.75) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Leucine SCHEMBL2057303 | 0.88 | SLC7A5 (0.75) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Dodecane SCHEMBL27450981 | 0.88 | SLC7A5 (0.75) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Norleucine SCHEMBL2785913 | 0.88 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Norleucine SCHEMBL8392 | 0.88 | — | — | |
| Norleucine SCHEMBL198127 | 0.88 | — | — | |
| Norleucine SCHEMBL5497693 | 0.88 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Norleucine SCHEMBL26474 | 0.88 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| Norleucine SCHEMBL5051846 | 0.88 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084137-A1 | PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2001-03-21 | — | — | EP | claimed |
| WO-1999064442-A1 | PEPTIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) | 1999-12-16 | — | — | WO | claimed |
| EP-3568411-B1 | METHODS AND COMPOSITIONS FOR TREATING HPA HYPERACTIVITY | SANNA PIETRO P (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11807693-B2 | Apelin polypeptides | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4257152-A2 | APELIN POLYPEPTIDES | Amgen Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3674314-B1 | APELIN POLYPEPTIDES | AMGEN INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3907237-A1 | APJ RECEPTOR AGONISTS AND USES THEREOF | Amgen Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11034745-B2 | Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones | ADEPTHERA LLC (US) | 2021-06-15 | — | — | US | disclosed |
| EP-2935311-B1 | APJ RECEPTOR AGONISTS AND USES THEREOF | AMGEN INC (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10941182-B2 | Apelin polypeptides | AMGEN INC. (US) | 2021-03-09 | — | — | US | disclosed |
| EP-2081602-A2 | TOXIN PEPTIDE THERAPEUTIC AGENTS | Amgen Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090118181-A1 | Compositions and methods for producing bioactive fusion proteins | AMGEN INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2008153745-A2 | COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS | AMGEN INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008088422-A2 | TOXIN PEPTIDE THERAPEUTIC AGENTS | AMGEN INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1940452-A2 | CGRP PEPTIDE ANTAGONISTS AND CONJUGATES | Amgen, Inc (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2008051383-A2 | USE OF ALCOHOL CO-SOLVENTS TO IMPROVE PEGYLATION REACTION YIELDS | AMGEN INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080020978-A1 | CGRP peptide antagonists and conjugates | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007048026-A2 | CGRP PEPTIDE ANTAGONISTS AND CONJUGATES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2000015605-A2 | CHIRAL CYANOAMINES AND METHODS OF PREPARATION | TRUSTEES OF BOSTON COLLEGE (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034745-B2 | Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones | RAMP1, CALCRL, RAMP3 | SLC7A5 1607/4885SLC1A2 3122/4885SLC1A1 2797/4885 |
| US-20090118181-A1 | Compositions and methods for producing bioactive fusion proteins | HGFAC, HDGF, GRB2 | SLC7A5 4389/4885SLC1A2 4857/4885SLC1A1 4852/4885 |
| US-20080020978-A1 | CGRP peptide antagonists and conjugates | GRPR, CALCRL, CALCA | SLC7A5 1499/4885SLC1A2 476/4885SLC1A1 585/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | SLC7A5 1526/4885SLC1A2 2213/4885SLC1A1 1874/4885 |
| US-10941182-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | SLC7A5 3758/4885SLC1A2 3217/4885SLC1A1 1928/4885 |
| US-11807693-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | SLC7A5 3758/4885SLC1A2 3217/4885SLC1A1 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.